Terms: = Kidney tumors AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Staging
4 results:
1. Toxicity profile of treatment with pd-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study.
Duarte HS; Veiga CRP; Veiga CP; Wainstein AJA; Drummond-Lage AP
Int Immunopharmacol; 2022 Jul; 108():108727. PubMed ID: 35397393
[TBL] [Abstract] [Full Text] [Related]
2. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.
Smith CC; Beckermann KE; Bortone DS; De Cubas AA; Bixby LM; Lee SJ; Panda A; Ganesan S; Bhanot G; Wallen EM; Milowsky MI; Kim WY; Rathmell WK; Swanstrom R; Parker JS; Serody JS; Selitsky SR; Vincent BG
J Clin Invest; 2018 Nov; 128(11):4804-4820. PubMed ID: 30137025
[TBL] [Abstract] [Full Text] [Related]
3. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.
Rossi S; Toschi L; Castello A; Grizzi F; Mansi L; Lopci E
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2310-2325. PubMed ID: 28815334
[TBL] [Abstract] [Full Text] [Related]
4. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
[TBL] [Abstract] [Full Text] [Related]
